Glycogen synthase kinase (GSK-3) is upregulated in many types of tumor, including prostate cancer. GSK-3 inhibitors reduce prostate tumor cell growth; however, it is not clear if both isoforms, GSK-3α and GSK-3β, are involved.To read more, a FREE Urotoday registration is required. Click here to register or login above.
To read UIJ content, a separate subscription is required.